World's Best Scientists 2026 revealed!
Andrés Cervantes

Andrés Cervantes

D-Index & Metrics

Medicine

D-Index
105
Citations
63972
World Ranking
6653
National Ranking
98

Overview

Andrés Cervantes is affiliated with the University of Valencia in Spain and has a significant presence in the field of Medicine, particularly in Oncology. Their research contributions span a variety of subfields, including Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology, and Surgery.

The scientist's work focuses on key topics such as Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, Gastric Cancer Management and Outcomes, Genetic Factors in Colorectal Cancer, Colorectal Cancer Surgical Treatments, and Pancreatic and Hepatic Oncology Research.

Among their recent publications are the following papers:

  • Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2022, Annals of Oncology)
  • Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial (2020, The Lancet Oncology)
  • Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2022, Annals of Oncology)
  • Clinical management of metastatic colorectal cancer in the era of precision medicine (2022, CA A Cancer Journal for Clinicians)
  • Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver (2021, Cancer Cell)

The scientist frequently collaborates with other researchers. Their most frequent co-authors include Valentina Gambardella, Josep Tabernero, Noelia Tarazona, Susana Roselló, and Tania Fleitas.

Publication venues where they commonly publish include Annals of Oncology, ESMO Open, Journal of Clinical Oncology, Cancer Research, and Cancer Treatment Reviews.

Best Publications

  • Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

    A. de Gramont;A. Figer;M. Seymour;M. Homerin

  • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    E. Van Cutsem;A. Cervantes;R. Adam;A. Sobrero

  • A phase 3 trial of bevacizumab in ovarian cancer.

    Timothy J Perren;Ann Marie Swart;Jacobus Pfisterer;Jonathan A Ledermann

  • ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

    H J Schmoll;E Van Cutsem;A Stein;V Valentini

  • Capecitabine as Adjuvant Treatment for Stage III Colon Cancer

    Chris Twelves;Alfred Wong;Marek P. Nowacki;Markus Abt

  • Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Bengt Glimelius;Lars Påhlman;A. Cervantes

  • Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    R. Labianca;B. Nordlinger;G. D. Beretta;S. Mosconi

  • Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

    Marc Peeters;Timothy Jay Price;Andrés Cervantes;Alberto F. Sobrero

  • Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    E. Van Cutsem;A. Cervantes;B. Nordlinger;D. Arnold

  • Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

    A. Okines;M. Verheij;W. Allum;D. Cunningham

  • Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.

    Renu R Bahadoer;Esmée A Dijkstra;Boudewijn van Etten;Corrie A M Marijnen;Corrie A M Marijnen

  • OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study

    Christophe Tournigand;Andres Cervantes;Arie Figer;Gérard Lledo

  • Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.

    D. Arnold;B. Lueza;J.-Y. Douillard;M. Peeters

  • Anal cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up

    Robert Glynne-Jones;Per J. Nilsson;Carlo Aschele;Vicky Goh

  • Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

    Amit M. Oza;Adrian D. Cook;Jacobus Pfisterer;Andrew Embleton

  • First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

    Josep Tabernero;Geoffrey I. Shapiro;Patricia M. LoRusso;Andres Cervantes

  • Integration of oncology and palliative care: a Lancet Oncology Commission

    Stein Kaasa;Jon Håvard Loge;Matti S. Aapro;Tit Albreht

  • Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

    Gordon John Sampson Rustin;Ignace Vergote;Elizabeth Eisenhauer;Eric Pujade-Lauraine

  • Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up

    T. Waddell;M. Verheij;W. Allum;D. Cunningham

  • Gastric cancer: epidemiology, pathology and treatment

    S. R. Alberts;A. Cervantes;C. J. H. van de Velde

Frequent Co-Authors

Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Bengt Glimelius
Bengt Glimelius Uppsala University
Fortunato Ciardiello
Fortunato Ciardiello University of Campania "Luigi Vanvitelli"
Michel Ducreux
Michel Ducreux Institut Gustave Roussy
David Cunningham
David Cunningham Royal Marsden NHS Foundation Trust
José Baselga
José Baselga Memorial Sloan Kettering Cancer Center
Gina Brown
Gina Brown Imperial College London
Thierry André
Thierry André Université Paris Cité
Ian Chau
Ian Chau Royal Marsden NHS Foundation Trust

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degree options in medicine and healthcare reveals a growing demand for flexible and accelerated programs. Many students seek ways to advance their careers quickly, which is why the fastest msn to dnp program is an attractive option. These programs allow registered nurses to move efficiently into higher-level clinical and leadership roles.

Affordability is another key consideration. If cost is a concern, there are many affordable dnp programs available online that provide quality education without excessive debt. For those eager to begin working quickly, a fast track medical lpn program can be a strategic start, leading to entry-level positions in healthcare in less time.

Specialization also matters. The shortest post master's pmhnp online programs offer a focused pathway for those wanting to serve in psychiatric mental health, addressing the growing need for mental health professionals. These online career pathways provide flexible, accessible opportunities for advancement in medicine.

Best Scientists Citing Andrés Cervantes

Trending Scientists

Recently Published Articles